½ÃÀ庸°í¼­
»óǰÄÚµå
1792296

Ç÷°ü³» µ¿¸Æ·ù ¼öº¹ ½ÃÀå º¸°í¼­(2025-2033³â) : ÀûÀÀÁõº°, Á¦Ç°º°, ¼ºº°, ¿¬·Éº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°

Endovascular Aneurysm Repair Market Report by Indication (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, and Others), Product, Gender, Age, End-User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 145 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç÷°ü³» µ¿¸Æ·ù º¹±¸(EVAR) ½ÃÀå ±Ô¸ð´Â 2024³â 31¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2025-2033³â¿¡ °ÉÄ£ ¼ºÀå·ü(CAGR)Àº 3.94%¸¦ ³ªÅ¸³»¸ç ½ÃÀå ±Ô¸ð°¡ 2033³â¿¡´Â 44¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

µ¿¸Æ·ù¶õ µ¿¸Æº®ÀÇ Ãë¾àÈ­¿Í º¯¼º¿¡ ÀÇÇÑ È®´ë¸¦ ¸»ÇÕ´Ï´Ù. µ¿¸Æ·ù´Â ÀϹÝÀûÀ¸·Î ´ã¹è ¼Òºñ ¹× Èí¿¬°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. µ¿¸Æ·ùÀÇ À¯º´·üÀº Á×»ó µ¿¸Æ °æÈ­Áõ, ³ôÀº ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡, °áÇÕ Á¶Á÷ Àå¾Ö¿Í °°Àº º´¸®ÇÐÀ» °¡Áø »ç¶÷µé »çÀÌ¿¡¼­µµ ³ô½À´Ï´Ù. Ç÷°ü³» µ¿¸Æ·ù ¼öº¹Àº ÀÌ·¯ÇÑ µ¿¸Æ·ù¸¦ ¼öº¹Çϱâ À§ÇØ ¼öÇàµÇ´Â Àúħ½À ¼ö¼úÀÔ´Ï´Ù. EVAR ÀýÂ÷´Â ÇǺ¹Çü ½ºÅÙÆ®(ÆÐºê¸¯ ·¹À̾î·Î µÑ·¯½Ñ ±Ý¼Ó ¸Þ½¬ Æ©ºê)¸¦ µ¿¸ÆÀÇ ¾àÇÑ ºÎºÐ¿¡ »ðÀÔÇÔÀ¸·Î½á ¼öÇàµË´Ï´Ù. ÀÌ·Î ÀÎÇØ Ç÷¾×ÀÌ ºÎÇ®¾î ¿À¸¥ ºÎºÐ¿¡ ½×ÀÌÁö ¾Ê°í È帣´Â °æ·Î°¡ È®º¸µÇ¾î ÆÄ¿­À» ¹æÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç, µ¿¸Æ·ùÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â ¿©·¯ ±â±¸°¡ ½ÃÆÇµÇ°í ÀÖ½À´Ï´Ù.

EVAR Ä¡·á´Â ¼ö¼úÀ» ÇÒ Çʿ䰡 ¾ø±â ¶§¹®¿¡ ÀüÅëÀûÀÎ Ä¡·á¹ýº¸´Ù ºñ±³Àû ¾ÈÀüÇÕ´Ï´Ù. ±× °á°ú ÀÌ ÀýÂ÷´Â ÀÔ¿ø ±â°£ÀÌ Âª°í ȸº¹µµ ºü¸¨´Ï´Ù. µ¿¸Æ·ùÀÇ À¯º´·ü°ú ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ç÷°ü³» Ä¡·á´Â °Ç°­ °ü¸® Á¦°ø¾÷ü¿¡ ÀÇÇØ Á¡Á¡ äÅõǰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¶ÇÇÑ ÀÌ·¯ÇÑ ÀýÂ÷ÀÇ ÀáÀçÀû ÀÌÁ¡¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿¡ ÀÇÇØ µÞ¹ÞħµË´Ï´Ù. ¶ÇÇÑ ¼¼°è Á¤ºÎ´Â ºñ¿ë ±¸Á¶¸¦ °³¼±Çϰí ȯÀÚµé »çÀÌ¿¡¼­ EVAR Àåºñ¿Í Ä¡·á¹ýÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀνÄÀ» ³ÐÈ÷±â À§ÇØ ¿©·¯ ÇÁ·Î±×·¥À» ½Ç½ÃÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÇ·á±â°üÀº º¸´Ù »¡¸® ȸº¹µÇ°í ÇÕº´ÁõÀÌ ÀûÀº EVAR ÀåÄ¡³ª ±â¼úÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ªÀº ¾ÈÂø ÁöÁ¡¿¡¼­ÀÇ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ°í µ¿¸Æ °î·ü¿¡ ´ëÇÑ ÀûÇÕ¼ºÀ» Çâ»ó½ÃŰ´Â °³¼±µÈ ÀÌ½ÄÆí ±â¼úÀÌ °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº EVAR ¼ö¼úÀÇ ¼º°ø·üÀ» ´õ¿í Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¼¼°èÀÇ Ç÷°ü³» µ¿¸Æ·ù º¹±¸ ½ÃÀåÀÇ ÇöÀç±îÁöÀÇ ÃßÀÌ¿Í ÇâÈÄ ¸î ³â°£ÀÇ ÃßÀÌ´Â?
  • »ê¾÷ÀÇ ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • ¼¼°èÀÇ Ç÷°ü³» µ¿¸Æ·ù º¹±¸ »ê¾÷¿¡¼­ COVID-19ÀÇ ¿µÇâÀº?
  • ÀûÀÀÁõ¿¡ µû¸¥ ½ÃÀå ºÐ¼®Àº?
  • Á¦Ç°¿¡ µû¸¥ ½ÃÀå ºÐ¼®Àº?
  • ¼ºº°¿¡ µû¸¥ ½ÃÀå ºÐ¼®Àº?
  • ¿¬·ÉÃþ¿¡ µû¸¥ ½ÃÀå ºÐ¼®Àº?
  • ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¸¥ ½ÃÀå ºÐ¼®Àº?
  • »ê¾÷ ¹ë·ùüÀÎÀÇ ´Ù¾çÇÑ ´Ü°è´Â?
  • »ê¾÷ÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â?
  • »ê¾÷ÀÇ ±¸Á¶¿Í ÁÖ¿ä ÁøÃâ±â¾÷Àº?
  • »ê¾÷ °æÀïµµ´Â?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Ç÷°ü³» µ¿¸Æ·ù ¼öº¹ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°
  • ½ÃÀå ºÐ¼® : Á¦Ç°º°
  • ½ÃÀå ºÐ¼® : ¼ºº°
  • ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°
  • ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°
  • ½ÃÀå ºÐ¼® : Áö¿ªº°
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

  • º¹ºÎ ´ëµ¿¸Æ·ù(AAA)
  • ÈäºÎ ´ëµ¿¸Æ·ù(TAA)
  • È亹ºÎ ´ëµ¿¸Æ·ù(TAAA)
  • ±âŸ

Á¦7Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • °æÇÇÀû EVAR
  • °³Ã¢Çü EVAR
  • ´ëµ¿¸Æ ½ºÅÙÆ®¿Í TAA ±×·¡ÇÁÆ®
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : ¼ºº°

  • ³²¼º
  • ¿©¼º

Á¦9Àå ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°

  • ¼Ò¾Æ
  • ¼ºÀÎ
  • ³ëÀÎ

Á¦10Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
  • Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦11Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • À¯·´
  • ºÏ¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«

Á¦12Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦13Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °¡°Ý ºÐ¼®

Á¦16Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Medtronic plc
    • Cook Group Incorporated
    • WL Gore & Associates, Inc.
    • Bolton Medical, Inc.
    • Gamida Cell Ltd.
    • JOTEC GmbH
    • Getinge AB(Maquet)
    • Shanghai MicroPort Medical(Group) Co., Ltd.
    • Terumo Corporation
    • Endologix, Inc.
    • Lombard Medical Limited
    • Cardinal Health, Inc.
CSM 25.08.27

The global endovascular aneurysm repair (EVAR) market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.4 Billion by 2033, exhibiting a growth rate (CAGR) of 3.94% during 2025-2033.

An aneurysm refers to the enlargement of the arterial wall due to weakness or degeneration. It is generally associated with tobacco consumption and smoking. The prevalence of aneurysms is also higher among people with medical conditions such as atherosclerosis, high cholesterol levels, and connective tissue disorder. Endovascular aneurysm repair (EVAR) refers to a minimally invasive procedure or surgery that is performed to repair these aneurysms. EVAR procedure is performed by inserting a covered stent, a metal mesh tube with a layer of fabric, into the weak area of the artery. This provides a route for the blood to flow without accumulating in the bulge and prevents it from bursting. Nowadays, multiple devices are available in the market that are used to treat aneurysms.

The EVAR treatment is comparatively safer than traditional procedures, as there is no need for performing surgery. As a result, this technique results in short hospital stays and quicker recovery. Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers. This has further been supported by the rising awareness of the potential benefits of the procedure. Also, governments across the globe are undertaking several programs to improve the cost structure and spread awareness about the availability of EVAR devices and treatment procedures among patients. In line with this, healthcare institutions are developing EVAR devices and technologies that offer faster recovery and fewer complications. For instance, enhanced graft technologies have been created, which allow treatments with short landing zones and improve conformability to the artery curvature. These technologies have further helped in increasing the success rate of EVAR procedures.

Key Market Segmentation:

Breakup by Indication:

  • Abdominal Aortic Aneurysm (AAA)
  • Thoracic Aortic Aneurysm (TAA)
  • Thoracoabdominal Aortic Aneurysm (TAAA)
  • Others

Breakup by Product:

  • Percutaneous EVAR
  • Fenestrated EVAR
  • Aortic Stents and TAA Grafts
  • Others

Breakup by Gender:

  • Male
  • Female

Breakup by Age:

  • Pediatric
  • Adult
  • Geriatric

Breakup by End-User:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

Breakup by Region:

  • Asia Pacific
  • Europe
  • North America
  • Middle East and Africa
  • Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Medtronic plc, Cook Group Incorporated, W. L. Gore & Associates, Inc., Bolton Medical, Inc., Gamida Cell Ltd., JOTEC GmbH, Getinge AB (Maquet), Shanghai MicroPort Medical (Group) Co., Ltd., Terumo Corporation, Endologix, Inc., Lombard Medical Limited, and Cardinal Health, Inc.

Key Questions Answered in This Report:

  • How has the global endovascular aneurysm repair market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the industry?
  • What has been the impact of COVID-19 on the global endovascular aneurysm repair industry?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the gender?
  • What is the breakup of the market based on the age?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the industry and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Endovascular Aneurysm Repair Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Product
  • 5.6 Market Breakup by Gender
  • 5.7 Market Breakup by Age
  • 5.8 Market Breakup by End-User
  • 5.9 Market Breakup by Region
  • 5.10 Market Forecast

6 Market Breakup by Indication

  • 6.1 Abdominal Aortic Aneurysm (AAA)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Thoracic Aortic Aneurysm (TAA)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Thoracoabdominal Aortic Aneurysm (TAAA)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Percutaneous EVAR
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Fenestrated EVAR
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Aortic Stents and TAA Grafts
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Gender

  • 8.1 Male
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Female
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Age

  • 9.1 Pediatric
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adult
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Geriatric
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Ambulatory Surgical Centers
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 Asia Pacific
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Europe
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 North America
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Middle East and Africa
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast
  • 11.5 Latin America
    • 11.5.1 Market Trends
    • 11.5.2 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porter's Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Medtronic plc
    • 16.3.2 Cook Group Incorporated
    • 16.3.3 W. L. Gore & Associates, Inc.
    • 16.3.4 Bolton Medical, Inc.
    • 16.3.5 Gamida Cell Ltd.
    • 16.3.6 JOTEC GmbH
    • 16.3.7 Getinge AB (Maquet)
    • 16.3.8 Shanghai MicroPort Medical (Group) Co., Ltd.
    • 16.3.9 Terumo Corporation
    • 16.3.10 Endologix, Inc.
    • 16.3.11 Lombard Medical Limited
    • 16.3.12 Cardinal Health, Inc.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦